Compare INDI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDI | LBRX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.0M | 850.5M |
| IPO Year | 2021 | N/A |
| Metric | INDI | LBRX |
|---|---|---|
| Price | $4.06 | $28.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $6.25 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 5.7M | 126.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $217,394,000.00 | N/A |
| Revenue This Year | $25.54 | N/A |
| Revenue Next Year | $38.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.33 | N/A |
| 52 Week Low | $2.32 | $13.40 |
| 52 Week High | $6.05 | $33.47 |
| Indicator | INDI | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 48.58 |
| Support Level | $4.03 | $22.39 |
| Resistance Level | $4.11 | $33.47 |
| Average True Range (ATR) | 0.41 | 1.68 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 18.98 | 48.88 |
Indie Semiconductor Inc caters to the autotech industry with semiconductors, photonics, and software platforms. The company's products include devices for a multitude of automotive applications spanning vision and radar processors, in-cabin wireless charging and USB power delivery, device interfacing through Apple CarPlay and Android Auto, and high-speed video and data connectivity. New products under evaluation or development include LiDAR, cybersecurity-enabled microcontrollers, and sensor-fusion processors. Its Photonics division mainly offers low-noise lasers, standard, and custom light sources. Geographically, the company generates the majority of its revenue from Greater China and the rest from the United States, Europe, South Korea, and other regions.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.